Clinical Endoscopy

  • 제55권3호
  • /
  • Pages.434-442
  • /
  • 2022
  • /
  • 2234-2400(pISSN)
  • /
  • 2234-2443(eISSN)
대한소화기내시경학회 (The Korean Society of Gastrointestinal Endoscopy)
권호 표지
DOI QR코드

DOI QR Code

Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study

  • 투고 : 2021.05.17
  • 심사 : 2021.07.11
  • 발행 : 2022.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Covered self-expandable metallic stents (CMSs) are widely used for malignant distal biliary obstructions (MDBOs) caused by pancreatic carcinoma. This study compared the efficacy and safety of the laser-cut-type and braided-type CMSs. Methods: To palliate MDBOs caused by pancreatic carcinoma, the laser-cut-type CMSs was used from April 2014 to March 2017, and the braided-type CMSs was used from April 2017 to March 2019. The tested self-expandable metallic stents were equipped with different anti-migration systems. Results: In total, 47 patients received CMSs for MDBOs (24 laser-cut type, 23 braided-type). The time to recurrent biliary obstruction (TRBO) was significantly longer in the braided-type CMSs (p=0.0008), and the median time to stent dysfunction or patient death was 141 and 265 days in the laser-cut-type CMSs and braided-type CMSs, respectively (p=0.0023). Stent migration was the major cause of stent dysfunction in both groups, which occurred in 37.5% of the laser-cut-type CMSs and 13.0% of the braided-type CMSs. There were no differences in the survival duration between the groups. Conclusions: The TRBO was significantly longer for the braided-type CMSs with an anti-migration system than for the laser-cut-type. Stent migration tended to be less frequent with the braided-type CMSs than with the laser-cut-type CMSs.

키워드

참고문헌

  1. Soehendra N, Reynders-Frederix V. Palliative bile duct drainage: a new endoscopic method of introducing a transpapillary drain. Endoscopy 1980;12:8-11.  https://doi.org/10.1055/s-2007-1021702
  2. Huibregtse K, Tytgat GN. Palliative treatment of obstructive jaundice by transpapillary introduction of large bore bile duct endoprosthesis. Gut 1982;23:371-375.  https://doi.org/10.1136/gut.23.5.371
  3. Walta DC, Fausel CS, Brant B. Endoscopic biliary stents and obstructive jaundice. Am J Surg 1987;153:444-447.  https://doi.org/10.1016/0002-9610(87)90787-2
  4. Speer AG, Cotton PB, MacRae KD. Endoscopic management of malignant biliary obstruction: stents of 10 French gauge are preferable to stents of 8 French gauge. Gastrointest Endosc 1988;34:412-417.  https://doi.org/10.1016/S0016-5107(88)71407-8
  5. Huibregtse K, Cheng J, Coene PP, et al. Endoscopic placement of expandable metal stents for biliary strictures: a preliminary report on experience with 33 patients. Endoscopy 1989;21:280-282.  https://doi.org/10.1055/s-2007-1012969
  6. Davids PH, Groen AK, Rauws EA, et al. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:1488-1492.  https://doi.org/10.1016/0140-6736(92)92752-2
  7. Knyrim K, Wagner HJ, Pausch J, et al. A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. Endoscopy 1993;25:207-212.  https://doi.org/10.1055/s-2007-1010294
  8. Lammer J, Hausegger KA, Fluckiger F, et al. Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. Radiology 1996;201:167-172.  https://doi.org/10.1148/radiology.201.1.8816539
  9. Prat F, Chapat O, Ducot B, et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998;47:1-7.  https://doi.org/10.1016/S0016-5107(98)70291-3
  10. Isayama H, Yasuda I, Ryozawa S, et al. Results of a Japanese multicenter, randomized trial of endoscopic stenting for non-resectable pancreatic head cancer (JM-test): covered wallstent versus double-layer stent. Dig Endosc 2011;23:310-315.  https://doi.org/10.1111/j.1443-1661.2011.01124.x
  11. Isayama H, Komatsu Y, Tsujino T, et al. A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 2004;53:729-734.  https://doi.org/10.1136/gut.2003.018945
  12. Kitano M, Yamashita Y, Tanaka K, et al. Covered self-expandable metal stents with an anti-migration system improve patency duration without increased complications compared with uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a randomized multicenter trial. Am J Gastroenterol 2013;108:1713-1722.  https://doi.org/10.1038/ajg.2013.305
  13. Misra SP, Dwivedi M. Reflux of duodenal contents and cholangitis in patients undergoing self-expanding metal stent placement. Gastrointest Endosc 2009;70:317-321.  https://doi.org/10.1016/j.gie.2008.12.054
  14. Okamoto T, Fujioka S, Yanagisawa S, et al. Placement of a metallic stent across the main duodenal papilla may predispose to cholangitis. Gastrointest Endosc 2006;63:792-796.  https://doi.org/10.1016/j.gie.2005.05.015
  15. Kin T, Ishii K, Okabe Y, et al. Feasibility of biliary stenting to distal malignant biliary obstruction using a novel designed metal stent with duckbill-shaped anti-reflux valve. Dig Endosc 2021;33:648-655.  https://doi.org/10.1111/den.13827
  16. Kogure H, Ryozawa S, Maetani I, et al. A prospective multicenter study of a fully covered metal stent in patients with distal malignant biliary obstruction: WATCH-2 study. Dig Dis Sci 2018;63:2466-2473.  https://doi.org/10.1007/s10620-017-4875-5
  17. Park DH, Kim MH, Choi JS, et al. Covered versus uncovered wallstent for malignant extrahepatic biliary obstruction: a cohort comparative analysis. Clin Gastroenterol Hepatol 2006;4:790-796.  https://doi.org/10.1016/j.cgh.2006.03.032
  18. Isayama H, Mukai T, Itoi T, et al. Comparison of partially covered nitinol stents with partially covered stainless stents as a historical control in a multicenter study of distal malignant biliary obstruction: the WATCH study. Gastrointest Endosc 2012;76:84-92.  https://doi.org/10.1016/j.gie.2012.02.039
  19. Kim JY, Ko GB, Lee TH, et al. Partially covered metal stents may not prolong stent patency compared to uncovered stents in unresectable malignant distal biliary obstruction. Gut Liver 2017;11:440-446.  https://doi.org/10.5009/gnl16245
  20. Conio M, Mangiavillano B, Caruso A, et al. Covered versus uncovered self-expandable metal stent for palliation of primary malignant extrahepatic biliary strictures: a randomized multicenter study. Gastrointest Endosc 2018;88:283-291.e3.  https://doi.org/10.1016/j.gie.2018.03.029
  21. Kullman E, Frozanpor F, Soderlund C, et al. Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. Gastrointest Endosc 2010;72:915-923.  https://doi.org/10.1016/j.gie.2010.07.036
  22. Telford JJ, Carr-Locke DL, Baron TH, et al. A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction. Gastrointest Endosc 2010;72:907-914.  https://doi.org/10.1016/j.gie.2010.08.021
  23. Yang MJ, Kim JH, Yoo BM, et al. Partially covered versus uncovered self-expandable nitinol stents with anti-migration properties for the palliation of malignant distal biliary obstruction: a randomized controlled trial. Scand J Gastroenterol 2015;50:1490-1499.  https://doi.org/10.3109/00365521.2015.1057219
  24. Ung KA, Stotzer PO, Nilsson A, et al. Covered and uncovered self-expandable metallic Hanarostents are equally efficacious in the drainage of extrahepatic malignant strictures: results of a double-blind randomized study. Scand J Gastroenterol 2013;48:459-465.  https://doi.org/10.3109/00365521.2012.758766
  25. Costamagna G, Tringali A, Reddy DN, et al. A new partially covered nitinol stent for palliative treatment of malignant bile duct obstruction: a multicenter single-arm prospective study. Endoscopy 2011;43:317-324.  https://doi.org/10.1055/s-0030-1256294
  26. Gomez-Oliva C, Guarner-Argente C, Concepcion M, et al. Partially covered self-expanding metal stent for unresectable malignant extrahepatic biliary obstruction: results of a large prospective series. Surg Endosc 2012;26:222-229.  https://doi.org/10.1007/s00464-011-1858-z
  27. Soderlund C, Linder S, Bergenzaun PE, et al. Nitinol versus steel partially covered self-expandable metal stent for malignant distal biliary obstruction: a randomized trial. Endoscopy 2014;46:941-948.  https://doi.org/10.1055/s-0034-1377936
  28. Yokota Y, Fukasawa M, Takano S, et al. Partially covered metal stents have longer patency than uncovered and fully covered metal stents in the management of distal malignant biliary obstruction: a retrospective study. BMC Gastroenterol 2017;17:105. 
  29. Isayama H, Nakai Y, Toyokawa Y, et al. Measurement of radial and axial forces of biliary self-expandable metallic stents. Gastrointest Endosc 2009;70:37-44.  https://doi.org/10.1016/j.gie.2008.09.032
  30. Isayama H, Hamada T, Yasuda I, et al. TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc 2015;27:259-264.  https://doi.org/10.1111/den.12379
  31. ASGE Standards of Practice Committee, Chandrasekhara V, Khashab MA, et al. Adverse events associated with ERCP. Gastrointest Endosc 2017;85:32-47.  https://doi.org/10.1016/j.gie.2016.06.051
  32. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.  https://doi.org/10.1016/j.ejca.2008.10.026
  33. Kanda Y. Investigation of the freely available easy-to-use software "EZR" for medical statistics. Bone Marrow Transplant 2013;48:452-458.  https://doi.org/10.1038/bmt.2012.244
  34. Yokoe M, Hata J, Takada T, et al. Tokyo guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci 2018;25:41-54.  https://doi.org/10.1002/jhbp.515
  35. Isayama H, Kawakubo K, Nakai Y, et al. A novel, fully covered laser-cut nitinol stent with antimigration properties for nonresectable distal malignant biliary obstruction: a multicenter feasibility study. Gut Liver 2013;7:725-730.  https://doi.org/10.5009/gnl.2013.7.6.725
  36. Saito K, Nakai Y, Isayama H, et al. A prospective multicenter study of partially covered metal stents in patients receiving neoadjuvant chemotherapy for resectable and borderline resectable pancreatic cancer: BTSNAC study. Gut Liver 2021;15:135-141.  https://doi.org/10.5009/gnl19302
  37. Marui S, Uza N, Yamazaki H, et al. Utility of laser-cut covered self-expandable metal stents for unresectable malignant distal biliary obstruction: a single-center experience. Endoscopy 2020;52:664-668.  https://doi.org/10.1055/a-1149-1700
  38. Park DH, Lee SS, Lee TH, et al. Anchoring flap versus flared end, fully covered self-expandable metal stents to prevent migration in patients with benign biliary strictures: a multicenter, prospective, comparative pilot study (with videos). Gastrointest Endosc 2011;73:64-70.  https://doi.org/10.1016/j.gie.2010.09.039
  39. Minaga K, Kitano M, Imai H, et al. Evaluation of anti-migration properties of biliary covered self-expandable metal stents. World J Gastroenterol 2016;22:6917-6924.  https://doi.org/10.3748/wjg.v22.i30.6917
  40. Nakai Y, Isayama H, Mukai T, et al. Impact of anticancer treatment on recurrent obstruction in covered metallic stents for malignant biliary obstruction. J Gastroenterol 2013;48:1293-1299.  https://doi.org/10.1007/s00535-013-0749-6
  41. Nakai Y, Isayama H, Kogure H, et al. Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer. J Gastroenterol Hepatol 2014;29:1744-1749.  https://doi.org/10.1111/jgh.12602
  42. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825.  https://doi.org/10.1056/NEJMoa1011923
  43. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-1703. https://doi.org/10.1056/NEJMoa1304369